{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:13:43Z","timestamp":1768299223576,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JA Clin Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Due to the highly invasive nature of veno-arterial extracorporeal membrane oxygenation (VA-ECMO), advanced malignancy is considered a relative contraindication. We here report a patient with hemodynamic collapse secondary to metastatic lung cancer in whom bridging via VA-ECMO was successful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 35-year-old man with metastatic non-small cell lung cancer harboring a deletion in exon 19 of epidermal growth factor receptor developed acute right ventricular failure and hemodynamic collapse due to pulmonary tumor thrombotic microangiopathy. Because treatment with the targeted agent osimertinib had already been initiated and a rapid response was anticipated, VA-ECMO was instituted as a bridge to its therapeutic effect. The patient's hemodynamics stabilized within 7\u00a0days, permitting VA-ECMO decannulation. At the time of writing, the patient is continuing to undergo regular outpatient follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In carefully selected oncology patients with highly treatment-sensitive disease, short-term VA-ECMO may be an effective bridge to systemic therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40981-025-00839-z","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:22:18Z","timestamp":1764940938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging via extracorporeal cardiopulmonary resuscitation for hemodynamic collapse in a patient with metastatic lung cancer: a case report"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7577-9050","authenticated-orcid":false,"given":"Takayuki","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoe","family":"Kobiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsusmi","family":"Yakushiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hakozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"839_CR1","first-page":"228","volume":"26","author":"R Kalra","year":"2020","unstructured":"Kalra R, Kosmopoulos M, Goslar T, Raveendran G, Bartos JA, Yannopoulos D. Extracorporeal cardiopulmonary resuscitation for cardiac arrest. Curr Opin Crit Care. 2020;26:228\u201335.","journal-title":"Curr Opin Crit Care"},{"key":"839_CR2","first-page":"E166","volume":"7","author":"G Makdisi","year":"2015","unstructured":"Makdisi G, Wang I-W. Extra corporeal membrane oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015;7:E166-76.","journal-title":"J Thorac Dis"},{"key":"839_CR3","unstructured":"ELSO. Guidelines for Cardiopulmonary Extracorporeal Life Support Extracorporeal Life Support Organization, Version 1.4. Ann Arbor, MI, USA: 2017. www.elso.org."},{"key":"839_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/1097-0142(19900801)66:3<587::AID-CNCR2820660330>3.0.CO;2-J","volume":"66","author":"A von Herbay","year":"1990","unstructured":"von Herbay A, Illes A, Waldherr R, Otto HF. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 1990;66:587\u201392.","journal-title":"Cancer"},{"key":"839_CR5","doi-asserted-by":"publisher","first-page":"204589401985100","DOI":"10.1177\/2045894019851000","volume":"9","author":"RH Godbole","year":"2019","unstructured":"Godbole RH, Saggar R, Kamangar N. Pulmonary tumor thrombotic microangiopathy: a systematic review. Pulm Circ. 2019;9:2045894019851000.","journal-title":"Pulm Circ"},{"key":"839_CR6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3348\/jksr.2024.0084","volume":"85","author":"BK Kim","year":"2024","unstructured":"Kim BK, Kim Y, Lee KE. Sudden development of fatal pulmonary due to suspected pulmonary tumoral thrombotic microangiopathy among patients with cancer: case series of clinical and CT features in 10 patients. J Korean Soc Radiol. 2024;85:1169\u201382.","journal-title":"J Korean Soc Radiol"},{"key":"839_CR7","first-page":"127","volume":"8","author":"C-K Chen","year":"2018","unstructured":"Chen C-K. Pulmonary tumor thrombotic microangiopathy: case report and literature review. J Acute Med. 2018;8:127\u201331.","journal-title":"J Acute Med"},{"key":"839_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"839_CR9","doi-asserted-by":"publisher","first-page":"S366","DOI":"10.1161\/CIR.0000000000000916","volume":"142","author":"AR Panchal","year":"2020","unstructured":"Panchal AR, Bartos JA, Caba\u00f1as JG, Donnino MW, Drennan IR, Hirsch KG, et al. Part 3: Adult basic and advanced life support: 2020 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142:S366-468.","journal-title":"Circulation"},{"key":"839_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2022","unstructured":"Melosky B, Kambartel K, H\u00e4ntschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther. 2022;26:7\u201318.","journal-title":"Mol Diagn Ther"},{"key":"839_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-015-1966-0","volume":"72","author":"M Sheng","year":"2016","unstructured":"Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, et al. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Eur J Clin Pharmacol. 2016;72:1\u201311.","journal-title":"Eur J Clin Pharmacol"},{"key":"839_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"839_CR13","doi-asserted-by":"publisher","first-page":"16243","DOI":"10.1002\/cam4.6288","volume":"12","author":"X Teng","year":"2023","unstructured":"Teng X, Wu J, Liao J, Xu S. Advances in the use of ECMO in oncology patient. Cancer Med. 2023;12:16243\u201353.","journal-title":"Cancer Med"},{"issue":"Suppl 1","key":"839_CR14","first-page":"S82","volume":"87","author":"AA Khorana","year":"2012","unstructured":"Khorana AA. Cancer and coagulation. Am J Hematol. 2012;87(Suppl 1):S82\u20137.","journal-title":"Am J Hematol"},{"key":"839_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.21037\/apm.2017.11.01","volume":"7","author":"C Johnstone","year":"2017","unstructured":"Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med. 2017;7:265\u201373.","journal-title":"Ann Palliat Med"},{"key":"839_CR16","doi-asserted-by":"crossref","unstructured":"Safdar A, Bodey G, Armstrong D. Infections in patients with cancer: overview. Principles and Practice of Cancer Infectious Diseases. Totowa, NJ: Humana Press; 2011. pp. 3-15.","DOI":"10.1007\/978-1-60761-644-3_1"},{"key":"839_CR17","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.3390\/cancers14205004","volume":"14","author":"F Petrella","year":"2022","unstructured":"Petrella F, Zorzino L, Frassoni S, Bagnardi V, Casiraghi M, Bardoni C, et al. Intraoperative extra corporeal membrane oxygenator for lung cancer resections does not impact circulating tumor cells. Cancers (Basel). 2022;14:5004.","journal-title":"Cancers (Basel)"}],"container-title":["JA Clinical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-025-00839-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40981-025-00839-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-025-00839-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:02:35Z","timestamp":1768269755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40981-025-00839-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1186\/s40981-025-00839-z","relation":{},"ISSN":["2363-9024"],"issn-type":[{"value":"2363-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}